A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB2 Compared to Remicade in Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy

Trial Profile

A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB2 Compared to Remicade in Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Sponsors Samsung Bioepis
  • Most Recent Events

    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
    • 09 Jun 2016 Data from this trial was presented at the Annual European Congress of Rheumatology (EULAR 2016), according to a Biogen media release.
    • 08 Jun 2016 Data from this trial will be presented at the Annual European Congress on Rheumatology (EULAR 2016), according to a Samsung Bioepis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top